**Supplemental Table 2-1**. Clinical efficacy and survival evaluated by independent review committee (IRC) and investigator per RECIST v1.1 in melanoma subgroups. NE, not estimable.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Total** | **Acral** | **Mucosal** | **Non-acral cutaneous** | **Unknown origin** |
| Total n | 127 | 50 | 22 | 29 | 26 |
|  ORR (%)  |  |  |  |  |  |
|     IRC per RECIST v1.1 | 17.3 | 14.0 | 0 | 31.0 | 23.1 |
|     PI per RECIST v1.1 | 18.9 | 14.0 | 9.1 | 31.0 | 19.2 |
| DCR (%) |  |  |  |  |  |
|     IRC per RECIST v1.1 | 57.5 | 52.0 | 40.9 | 65.5 | 73.1 |
|     PI per RECIST v1.1 | 55.9 | 52.0 | 36.4 | 69.0 | 65.4 |
|  |  |  |  |  |  |
| mPFS by IRC (months) (95%CI) | 3.6 (2.2, 5.3) | 3.2 (1.8, 3.6) | 1.9 (1.8, 5.3) | 5.5 (1.9, 19.2) | 7.3 (3.5, 18.4) |
|    Censored, n (%) | 39 (30.7) | 12 (24.0) | 7 (31.8) | 10 (34.5) | 10 (38.5) |
|  Events, n (%) | 88 (69.3) | 38 (76.0) | 15 (68.2) | 19 (65.5) | 16 (61.5) |
|  |  |  |  |  |  |
| Median OS (months) (95%CI) | 22.2 (15.3, NE) | 16.9(10.9, NE) | 10.3(6.6, 16.5) | NE(15.3, NE) | NE(19.5, NE) |
|    Censored, n (%) | 66 (52.0) | 25 (50.0) | 6 (27.3) | 18 (62.1) | 17 (65.4) |
|    Death, n (%) | 61 (48.0) | 25 (50.0) | 16 (72.7) | 11 (37.9) | 9 (34.6) |

**Supplemental Table 2-2.** Top 20% TMB value in each subtype as cut-off for efficacy analysis. Cutaneous, non-acral cutaneous melanoma; Acral, acral melanoma; Mucosal, mucosal melanoma; Unknown, melanoma with unknown primary.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Cutaneous** | **Acral** | **Mucosal** | **Unknown** | **All** |
| **Number of patients** | 23 | 39 | 15 | 21 | 98 |
| **Overall ORR** | 30.4% | 10.3% | 0% | 23.8% | 16.3% |
| **TMB top 20% value (Muts/Mb)** | 3.6 | 4.2 | 3.2 | 4.2 | 3.6 |
| **ORR in top 20% TMB** | 40.0% | 25.00% | 0% | 50.0% | 30.0% |
| **ORR in bottom 80% TMB** | 27.8% | 6.5% | 0% | 17.6% | 12.8% |
|  ***p* value top vs bottom** | 0.62 | 0.18 | 1.00 | 0.23 | 0.088 |